Clinical Utility of Optical Genome Mapping as an Additional Tool in a Standard Cytogenetic Workup in Hematological Malignancies
Compared to SCGW, OGM detects additional cytogenomic aberrations in approximately 58% of cases. OGM provides clinical utility at varying rates across different types of hematological malignancies. Given these differences, strategic triaging can help maximize the clinical value of OGM by focusing on diseases where it offers the most significant benefit.
Authors
- L. Jeffrey Medeiros (ORCID: https://orcid.org/0000-0001-6577-8006)
- Gökçe Törüner (ORCID: https://orcid.org/0000-0002-5305-6337)
- Shimin Hu (ORCID: https://orcid.org/0000-0001-7110-3814)
- Qing Wei (ORCID: https://orcid.org/0000-0003-0141-9682)
- Chi Young Ok (ORCID: https://orcid.org/0000-0002-6822-7880)
- Guilin Tang (ORCID: https://orcid.org/0000-0002-9482-4806)
- Sanam Loghavi (ORCID: https://orcid.org/0000-0001-8980-3202)
- Rashmi Kanagal‐Shamanna (ORCID: https://orcid.org/0000-0001-7829-5249)
- Zhenya Tang (ORCID: https://orcid.org/0000-0002-8079-9945)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- Cancers
- Published
- 2025-04-25
- DOI
- https://doi.org/10.3390/cancers17091436
- Citations
- 14
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 24.78